Introduction
============

The multidrug resistant ATP-binding cassette efflux transporter ABCG2, encoded by the *ABCG2* gene in chromosome 4q22, is located in the membrane of various cells, including hepatocytes, renal cells, and enterocytes.[@b1-pgpm-11-205] Its main function is to reduce excessive exposure to toxins and drugs, including disease modifying anti-rheumatic drugs (DMARDs) such as methotrexate (MTX).[@b2-pgpm-11-205] ABCG2 transports not only MTX, but also its polyglutamate forms, specifically polyglutamate 2 and 3, and plays a key role in the absence of other transporters, such as ABCC2.[@b3-pgpm-11-205],[@b4-pgpm-11-205] The most common *ABCG2* single nucleotide polymorphism (SNP) is rs2231142, where the C nucleotide is substituted for A at position number 421 (C421A), resulting in loss of ABCG2 function.[@b4-pgpm-11-205] Although studies have claimed that rs2231142 SNP does not influence the clinical response to MTX,[@b5-pgpm-11-205] a recent study showed that *ABCG2* SNP influenced not only MTX treatment response but also its discontinuation.[@b6-pgpm-11-205] However, there is no conclusive evidence until now regarding the relationship between this SNP and MTX response rate in patients with rheumatoid arthritis (RA). We have recently reported that treatment with MTX is associated with lower blood pressure (BP) and pulse-wave velocity (PWV), a marker of arterial stiffness, in this group.[@b7-pgpm-11-205],[@b8-pgpm-11-205] These associations might explain, at least in part, the lower incidence of cardiovascular (CV) events in RA patients treated with MTX when compared to other DMARDs in epidemiological studies.[@b9-pgpm-11-205] Here, we seek to investigate the associations between the *ABCG2* C421A SNP on red blood cell MTX polyglutamate concentrations (MTXPGs), BP, and arterial stiffness in RA patients treated with MTX in our RA cohort.

Methods
=======

Patient recruitment and assessment have been described in detail elsewhere.[@b7-pgpm-11-205],[@b8-pgpm-11-205] Briefly, we studied a consecutive series of adult RA patients treated with MTX for at least 8 weeks. The study (registered in the Australian New Zealand Clinical Trials Registry, ACTRN12616001366448) was approved by the Southern Adelaide Clinical Human Research Ethics Committee (Ethics Approval Number: 76.14). Each participant gave an informed written consent before enrolling in the study.

MTXPGs, clinical and 24-hour peripheral and central BP, and markers of arterial stiffness (PWV and augmentation index, AIx) were assessed in two separate visits, at baseline and after 8-months.[@b7-pgpm-11-205],[@b8-pgpm-11-205] Genomic DNA was extracted from peripheral blood mononuclear cells. The concentration and purity of the samples was determined using a Nanodrop (Thermo Fisher Scientific, Waltham, MA, USA). The DNA was plated into a 96-well master plate at 5 ng/µL. The *ABCG2* 421C-A SNP (rs2231142) was determined by TaqMan^®^ SNP genotyping assays using an ABI 7500 Fast Real-Time PCR system (Applied Biosystems, Carlsbad, CA, USA). After genotyping, and due to the relatively low frequency of the A allele, participants were classified based on their *ABCG2* C421A status as: 1) loss of function, as determined by carriage of at least one copy of the A allele (ie., AA or AC genotype); or 2) normal function, or homozygote for the C allele (ie., CC genotype). Both the AC and CC groups were identified from within the same MTX-treated RA patient cohort, making the two genotype groups more likely to be comparable in terms of clinical and demographic characteristics.

Clinical peripheral SBP was the primary study end-point. Clinical peripheral diastolic BP (DBP), central BP, AIx, 24-hour peripheral and central BP, and PWV were secondary end-points. Based on our previous studies,[@b7-pgpm-11-205] a sample size of 56 RA patients treated with MTX provided 80% power (alpha=0.05) to detect a difference of 10 mmHg in SBP between the MTX and non-MTX groups. Variables were tested for normal distribution using the Kolmogorov-Smirnov test. Results are expressed as means ± SD, medians and interquartile ranges, or frequencies, as appropriate. Given the significant difference in age between the two genotype groups in this study, as well as the known impact of age on BP,[@b10-pgpm-11-205] AIx,[@b11-pgpm-11-205] and PWV,[@b12-pgpm-11-205] we calculated age-adjusted values prior to each comparison, and reported the age-adjusted means. We then combined the data from the baseline and 8-month visits and performed a between-genotype group comparison using a mixed effects model with adjustment for visit, age, gender, body mass index (BMI), and disease activity, as measured by the 28-joint Disease Activity Score (DAS28), which were included as fixed effects. The subject ID was included as a random intercept. Analyses were performed using Stata^®^ software version 14.2 (StataCorp, TX, USA).

Results
=======

The majority of RA patients carried the CC genotype (n=46) whereas the remaining 10 carried the AC genotype. The CC group was significantly older than the AC group (52±18.7 vs 63±11 years, *P*=0.01; [Table 1](#t1-pgpm-11-205){ref-type="table"}). The AC group had significantly lower age-adjusted peripheral and central SBP, and a trend towards lower peripheral and central DBP, when compared to the CC group ([Table 1](#t1-pgpm-11-205){ref-type="table"}). The mean 24-hour-peripheral and central SBP values were also significantly lower in the AC group ([Table 1](#t1-pgpm-11-205){ref-type="table"}). However, there were no significant between-group differences in AIx or PWV. After adjusting for MTX dose and duration, intracellular MTXPG concentrations were higher, albeit not significantly, in the AC group when compared to the CC group ([Table 1](#t1-pgpm-11-205){ref-type="table"}). There was, however, a moderate positive correlation between clinical SBP and the level of MTXPGs in CC genotypes of *ABCG2* SNP ([Figure 1](#f1-pgpm-11-205){ref-type="fig"}).

When data from both visits were combined in a mixed effects model with adjustment for age, gender, BMI, DAS28, and visit, there were no significant between-group differences in SBP, DPB, PWV, Alx, and MTXPGs ([Table 2](#t2-pgpm-11-205){ref-type="table"}).

Discussion
==========

This repeated cross-sectional study reported a significantly lower SBP, and a trend towards higher concentrations of MTXPGs, in RA patients with loss of function *ABCG2* C421A genotypes when compared to patients who were homozygote for the normal allele. Although no longer significant during repeated assessment, the trend in between-group differences in SBP and DBP was maintained. We cannot rule out the possibility that the study was underpowered to detect these smaller, although clinically important, average differences observed in the repeated analysis. A larger group of AC genotype patients is therefore required to confirm our findings.

A few studies have failed to show that *ABCG2* SNPs influence the clinical response to MTX.[@b5-pgpm-11-205],[@b13-pgpm-11-205] However, a recent study showed that *ABCG2* SNPs are associated with MTX response in RA patients.[@b6-pgpm-11-205] Moreover, another study showed that A homozygotes have a reduced function of the ABCG2 transporter (ie., reduced efflux capability of MTX).[@b14-pgpm-11-205] This results in greater MTX accumulation and better MTX response.[@b15-pgpm-11-205] Furthermore, RA carriers of the AC genotype show better disease activity.[@b16-pgpm-11-205] Although this was attributed to the DMARD sulphasalazine, 94% of the RA cohort was treated with MTX. In agreement with the latter studies, this study found that the mutant allele of *ABCG2* (AC) is associated with higher RBC accumulation of MTXPGs. The AC allele is associated with reduced function of the MTX transporter, hence greater MTXPG accumulation. Our preliminary results suggest that a higher concentration of MTXPGs, albeit not significant, might be associated with the reported differences in SBP between the AC and the CC groups. As suggested in our previous studies, MTXPGs inhibit aminoimidazole car-boxamide ribonucleotide transformylase.[@b17-pgpm-11-205] This leads to the accumulation of the substrate aminoimidazole carboxamide ribonucleotide and its metabolites which, in turn, inhibit adenosine deaminase and adenosine monophosphate deaminase.[@b17-pgpm-11-205] The accumulation of adenosine, with consequent BP lowering effects through peripheral and central mechanisms, might account for the reported differences in BP.[@b18-pgpm-11-205] Adenosine is known to cause vasodilation, either directly or through NO.[@b19-pgpm-11-205] Adenosine acts on the vascular endothelium via its receptors A1 and A2A and stimulates the release of PG, which enhances the release of nitric oxide (NO). Concurrently, adenosine acts centrally on the brain nucleus tractus, where adenosine activates endothelial NO synthase through A2A receptors. As a result, the level of NO is increased and thus, adenosine has a key role in modulating BP and arterial functions ([Figure 2](#f2-pgpm-11-205){ref-type="fig"}). The main strength of our study is the comprehensive repeated assessment of, clinical and over 24-hours, peripheral and central BP and markers of arterial stiffness. The limitations of our study include the lack of adenosine assessment and the possibility that the study might be underpowered to identify the somewhat smaller average differences in the repeated analysis. Due to inter-individual variability, genetic polymorphisms might provide essential information for a personalized approach to initiate the dose of MTX and subsequent monitoring. This MTX personalized approach could then be used to examine BP and arterial function effects of MTX on other high-risk patients with diseases other than RA---for example, designing randomized control trials for high-risk cardiac patients using MTX. Moreover, this genetic polymorphism could provide vital information in the field of molecular biology and genetic engineering. In particular, changing the sequence of the DNA intentionally is a known technique for introducing a mutation in a particular gene; it is also called site-specific mutagenesis. Researchers could use this finding in constructing novel MTX analogues that are characterized by combined anti-inflammatory and BP/arterial function effects. The CV-protective effects of MTX have a pharmacological attraction. MTX could be reused for managing CV risk in not only RA patients but also in the general population. It might provide useful information about the drug genetic variations that might assist physicians in personalizing the dose for high-risk patients. In conclusion, our study provides the first evidence of an association between genetic polymorphisms of MTX, and BP in RA patients. Further randomized-controlled studies are warranted to confirm these findings, and to establish whether these effects account for the reduced CV risk reported with MTX treatment.
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![Association between clinical peripheral SBP and MTXPGs polyglutamate concentrations in MTX *ABCG2* genotypes.\
**Abbreviations:** clinical SBP, clinical peripheral systolic blood pressure; MTXPGs, methotrexate polyglutamates.](pgpm-11-205Fig1){#f1-pgpm-11-205}

![Potential mechanisms explaining the effects of MTX on BP and arterial function in RA.\
**Abbreviations:** MTX, methotrexate; FPGs, Folylpolyglutamate synthetase enzyme; ATIC, 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase; NO, nitric oxide; eNOS, endothelial NO synthase; PG, prostaglandins; cGMP, cyclic guanosine-3′, 5-monophosphate; GTP, guanosine-5′-triphosphate; BP, blood pressure; PWV, pulse wave velocity; RA, rheumatoid arthritis.](pgpm-11-205Fig2){#f2-pgpm-11-205}

###### 

Baseline characteristics of subjects according to CC and AC genotyping of *ABCG2* SNP

                                                                           CC genotype (n=46)   AC genotype (n=10)   *P*-value
  ------------------------------------------------------------------------ -------------------- -------------------- --------------------------------------------------
                                                                                                                     
  Age, years (mean ± SD)                                                   63±11                52±18.7              0.01[b](#tfn3-pgpm-11-205){ref-type="table-fn"}
  Females, n (%)                                                           32 (69.6)            7 (70.0)             0.98
  Hypertension treatment, n (%)                                            15 (32.6)            1 (10.0)             0.15
  BMI (kg/m^3^)                                                            27.4±0.62            25.7±1.4             0.27
  MTX dose (mg/week)                                                       14.5±0.56            14±1.2               0.72
  [a](#tfn2-pgpm-11-205){ref-type="table-fn"}MTXPGs (nmol/L packed RBCs)   116.3±7              144.3±15.3           0.10
  CRP (mg/L)                                                               7±1.4                3.9±3.2              0.40
  DAS28 score                                                              2.8±1.1              2.6±0.2              0.55
  Stanford HAQ score                                                       0.69±0.08            0.89±0.18            0.33
  Clinical peripheral SBP (mmHg)                                           127.2±1.5            117±3.5              0.01[b](#tfn3-pgpm-11-205){ref-type="table-fn"}
  Clinical peripheral DBP (mmHg)                                           74.1±1.1             69±2.5               0.07[b](#tfn3-pgpm-11-205){ref-type="table-fn"}
  Clinical central SBP (mmHg)                                              117.9±1.4            107±3.2              0.003[c](#tfn4-pgpm-11-205){ref-type="table-fn"}
  Clinical central DBP (mmHg)                                              76±1.1               70.8±2.5             0.06
  24-hour peripheral SBP (mmHg)                                            119.8±1.9            109.2±4              0.02[b](#tfn3-pgpm-11-205){ref-type="table-fn"}
  24-hour peripheral DBP (mmHg)                                            70±1.2               65.7±2.5             0.13
  24-hour central SBP (mmHg)                                               116.4±1.4            108.9±3              0.02[b](#tfn3-pgpm-11-205){ref-type="table-fn"}
  24-hour central DBP (mmHg)                                               76±0.90              73±1.9               0.18
  AIx (%)                                                                  30.4±1.1             25.7±2.4             0.07[b](#tfn3-pgpm-11-205){ref-type="table-fn"}
  AIx @ 75bpm (%)                                                          28.1±0.90            26.03±2              0.36
  24-hour AIx @ 75bpm (%)                                                  29±0.75              26.6±1.6             0.19
  24-hour PWV (m/second)                                                   9.01±0.09            9.04±0.20            0.91

**Notes:** All group means, except for age, are age-adjusted.

Means are adjusted for MTX dose and duration.

*P*-value≤0.05.

*P*-value≤0.01. Data presented as mean ± standard deviation unless otherwise indicated.

**Abbreviations:** RBCs, red blood cells; BMI, body mass index; MTX, Methotrexate; MTXPGs, MTX polyglutamates; SBP, systolic blood pressure; DBP, diastolic blood pressure; AIx, Augmentation index; PWV, pulse wave velocity; CRP, C-reactive protein.

###### 

Adjusted mean (95% CI) differences in BP, AIx, PWV, and concentrations of MTXPGs between CC (n=46) and AC (n=10) polymorphisms of the MTX *ABCG2* SNP using combined data from baseline and 8 months

                                  Model 1               Model 2   Model 3                                          
  ------------------------------- --------------------- --------- -------------------- ------ -------------------- ------
                                                                                                                   
  Clinic peripheral SBP (mmHg)    6.2 (−3. 2, 15.5)     0.19      5.7 (−3.7, 15.1)     0.23   5.8 (−3.7, 15.4)     0.23
  Clinic peripheral DBP (mmHg)    1.9 (−4.4, 8.4)       0.55      1.7 (−4.7, 8.05)     0.61   1.4 (−5.03, 7.7)     0.68
  Clinic central SBP (mmHg)       7.3 (−1.7, 16.2)      0.11      7.0 (−2.0, 16.0)     0.13   7.02 (−2.1, 16.1)    0.13
  Clinic central DBP (mmHg)       2.7 (−3.7, 9.0)       0.41      2.3 (−4.0, 8.7)      0.47   1.9 (−4.4, 8.2)      0.56
  AIx \@75 (%)                    −1.1 (−6.5, 4.2)      0.68      −0.92 (−6.3, 4.4)    0.74   −0.81 (−6.2, 4.6)    0.77
  24-hour peripheral SBP (mmHg)   7.6 (−1.9, 17)        0.12      7.1 (−2.3, 16.4)     0.14   7.2 (−2.2, 16.6)     0.13
  24-hour peripheral DBP (mmHg)   3.9 (−1.3, 9.1)       0.14      3.5 (−1.6, 8.7)      0.18   3.4 (−1.8, 8.6)      0.20
  24-hour central SBP (mmHg)      4 (−2.9, 11.0)        0.26      3.1 (−3.7, 9.8)      0.37   3.4 (−3.3, 10.0)     0.32
  24-hour central DBP (mmHg)      1.8 (−2.2, 6.0)       0.38      1.4 (−2.7, 5.4)      0.52   1.6 (−2.5, 5.6)      0.45
  24-hour AIx \@75 (%)            1.3 (−2.5, 5.2)       0.50      1.3 (−2.5, 5.1)      0.50   1.6 (−2.2, 5.4)      0.42
  24-hour PWV (m/second)          −0.04 (−0.74, 0.66)   0.97      −0.1 (−0.76, 0.63)   0.85   −0.1 (−76, 0.65)     0.89
  MTXPGs (nmol/L)                 26.2 (−12.1, 64.5)    0.18      27.7 (−10.6, 65.9)   0.16   27.9 (−11.2, 67.0)   0.16

**Notes:** Model 1 = adjusted for age and visit; Model 2 = adjusted for age, visit, gender, and BMI; Model 3 = adjusted for age, visit, gender, BMI, and DAS28.

**Abbreviations:** BMI, body mass index; MTX, Methotrexate; MTXPGs, MTX polyglutamates; BP, blood pressure; SBP, systolic BP; DBP, diastolic BP; AIx, Augmentation index; PWV, pulse wave velocity; DAS28, Disease Activity Score.
